<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01513850</url>
  </required_header>
  <id_info>
    <org_study_id>Hepabulin IV_LT_lll_2011</org_study_id>
    <nct_id>NCT01513850</nct_id>
  </id_info>
  <brief_title>A Confirmatory Study of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients</brief_title>
  <official_title>A 52-week, Multi-center, Open Label, Single Arm, Phase 3 Study to Evaluate the Efficacy and Safety of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to Evaluate the efficacy and safety of Hepabulin IV (HBIG, a
      study drug) after liver transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 52-week, Multi-center, Open label, Single arm, Phase 3 Study to Evaluate the Efficacy and
      Safety of Hepabulin IV in HBsAg positive Liver Transplantation recipients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBV(HBsAg) recurrence</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>viral Marker of HBV</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Hepabulin IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hepabulin IV</intervention_name>
    <description>I.V.</description>
    <arm_group_label>Hepabulin IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HBsAg Positive candidate for HBV-related liver transplant

          -  Primary, single organ recipients

          -  written informed consent

        Exclusion Criteria:

          -  acute renal failure, Serum creatinin &gt;1.5*ULN

          -  severe cardiac disease or other significant disease

          -  HAV, HCV or HIV positive

          -  Immunoglobulin A deficiency.

          -  History of hypersensitivity to Human Immunoglobulin.

          -  History of cancer within 5 years. (without HCC)

          -  History of alcohol or/and drug abuse.

          -  History organ transplantation.

          -  Within 30 days, participation in another clinical trial and use of an investigational
             product.

          -  Subject suffer from any acute or chronic medical, surgical or psychiatric condition or
             laboratory abnormality that, may increase the risk associated with the study
             participation or investigational product administration, or may interfere with the
             interpretation of study result.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Goo Kim, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>St.Mary's Hospital, Catholic University Medical college</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SKChemicals</name>
      <address>
        <city>Seongnam</city>
        <state>Gyunggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2012</study_first_submitted>
  <study_first_submitted_qc>January 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2012</study_first_posted>
  <last_update_submitted>May 29, 2015</last_update_submitted>
  <last_update_submitted_qc>May 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver Transplantation</keyword>
  <keyword>HBV</keyword>
  <keyword>HBV Recurrence</keyword>
  <keyword>HBsAg Positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

